Accueil   Diary - News   All news Theranexus announces issuance of european patent covering its drug candidate THN102 for treatment of narcolepsy and parkinson’s disease

Theranexus announces issuance of european patent covering its drug candidate THN102 for treatment of narcolepsy and parkinson’s disease

 

 

 

Lyon, 11 January 2018 – Theranexus, an innovative biopharmaceutical company that focuses on the treatment of diseases of the central nervous system, today announces that it has obtained a European patent for its drug candidate THN102, primarily covering the treatment of narcolepsy and excessive daytime sleepiness associated with Parkinson’s disease. The patent was issued to the French Alternative Energies and Atomic Energy Commission (CEA) on 3 January 2018 by the European Patent Office (EPO). CEA granted Theranexus a worldwide exclusive licence.

 


The patent, numbered EP3024458, names Franck Mouthon (CEO) and Mathieu Charvériat (CSO) as the inventors and is entitled “Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug”. It protects drug candidate THN102, which combines flecainide as an anti-connexin agent and modafinil as a psychotropic drug, and expires in 2034 (not including Supplementary Protection Certificate). The patent was obtained primarily on the basis of preclinical results published in the prestigious journal Sleep in 2016 that demonstrated the positive effects of THN102 on the two cardinal symptoms of narcolepsy: excessive daytime sleepiness and episodes of cataplexy.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree